|
MediciNova Reports Fourth Quarter and Full Year 2010 Results
TradersHuddle.com The decrease in research and development expenses primarily related to the completion of the clinical trial evaluating MN-221 at planned escalating doses in patients with severe acute exacerbations of asthma treated in emergency departments in 2009 and … |
View full post on asthma – Google News